| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $10.9M | +4.0% | -3.4% |
| SG&A Expense | $4.5M | +4.9% | +12.3% |
| Operating Income | -$15.4M | -4.2% | -0.7% |
| Net Income | -$15.0M | -3.7% | -2.5% |
| EPS (Basic) | -$0.38 | +5.0% | +22.4% |
| EPS (Diluted) | -$0.38 | +5.0% | +22.4% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $227.6M | +763.4% | +403.4% |
| Current Assets | $229.1M | +726.3% | +314.6% |
| Total Assets | $241.1M | +501.8% | +251.6% |
| Current Liabilities | $9.5M | +27.5% | +37.9% |
| Total Liabilities | $13.1M | +17.6% | +20.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$35.5M | — | — |
| Capital Expenditures | $18K | — | — |
| Investing Cash Flow | -$18K | — | — |
| Financing Cash Flow | $226.9M | — | — |
| Free Cash Flow | -$35.5M | — | — |
| $228.0M |
| +687.9% |
| +295.0% |